ASK1 is a novel molecular target for preventing aminoglycoside-induced hair cell death

Jacqueline M. Ogier1,2,3 · Yujing Gao1,2 · Eileen M. Dunne2,4 · Michael A. Wilson1 · Sarath C. Ranganathan2,5,6 · Gregory H. Tesch7 · David J. Nikolic Paterson7 · Alain Dabdoub3 · Rachel A. Burt1 · Bryony A. Nayagam8,9 · Paul J. Lockhart1,2

Received: 9 June 2021 / Revised: 7 February 2022 / Accepted: 3 March 2022 / Published online: 26 April 2022
© The Author(s) 2022, corrected publication 2022

Abstract
Aminoglycoside antibiotics are lifesaving medicines, crucial for the treatment of chronic or drug resistant infections. However, aminoglycosides are toxic to the sensory hair cells in the inner ear. As a result, aminoglycoside-treated individuals can develop permanent hearing loss and vestibular impairment. There is considerable evidence that reactive oxygen species (ROS) production and the subsequent phosphorylation of c-Jun N-terminal kinase (JNK) and P38 mitogen-activated protein kinase (P38) drives apoptosis in aminoglycoside-treated hair cells. However, treatment strategies that directly inhibit ROS, JNK, or P38 are limited by the importance of these molecules for normal cellular function. Alternatively, the upstream regulator apoptosis signal-regulating kinase 1 (ASK1/MAP3K5) is a key mediator of ROS-induced JNK and P38 activation under pathologic but not homeostatic conditions. We investigated ASK1 as a mediator of drug-induced hair cell death using cochlear explants from Ask1 knockout mice, demonstrating that Ask1 deficiency attenuates neomycin-induced hair cell death. We then evaluated pharmacological inhibition of ASK1 with GS-444217 as a potential otoprotective therapy. GS-444217 significantly attenuated hair cell death in neomycin-treated explants but did not impact aminoglycoside efficacy against P. aeruginosa in the broth dilution test. Overall, we provide significant pre-clinical evidence that ASK1 inhibition represents a novel strategy for preventing aminoglycoside ototoxicity.

Key messages
• ASK1 is an upstream, redox-sensitive regulator of P38 and JNK, which are known mediators of hair cell death.
• Ask1 knockout does not affect hair cell development in vivo, but significantly reduces aminoglycoside-induced hair cell death in vitro.
• A small-molecule inhibitor of ASK1 attenuates neomycin-induced hair cell death, and does not impact antibiotic efficacy in vitro.
• ASK1 may be a novel molecular target for preventing aminoglycoside-induced hearing loss.

Keywords Hair cell · Ototoxic · MAP3K5 · p38 · JNK · Hearing
Introduction

Aminoglycoside antibiotics are used for serious or drug resistant infections of the respiratory tract, urinary tract, central nervous system or intra-abdominal organs, as well as endocarditis or sepsis (in adults and neonates), and prophylactically during and post-surgery. Aminoglycoside therapies preserve life; however, negative side effects are associated with their use. Careful dosing and monitoring regimens limit toxic outcomes, including encephalopathy, neuromuscular blockade, and nephrotoxicity [1]. However, ototoxicity (toxic outcomes relating to the ear) remains a persistent problem.

Aminoglycoside ototoxicity predominantly manifests as irreversible damage to the sensory hair cells (HCs) of the cochlea and vestibular apparatus. Therefore, aminoglycoside-treated individuals can experience permanent damage to their hearing and/or balance. The reported prevalence of aminoglycoside-induced ototoxic outcomes is variable (Table 1). Nevertheless, for those affected, ototoxicity has a profound effect on their quality of life [2, 3]. Currently, treatment can cause permanent damage to their hearing and/or balance. The reported prevalence of aminoglycoside-induced ototoxic outcomes is variable (Table 1). Nevertheless, for those affected, ototoxicity has a profound effect on their quality of life [2, 3]. Currently, no treatment exists for the prevention of aminoglycoside-induced ototoxicity. Instead, clinical practice aims to minimise or avoid aminoglycoside use. However, an alternate therapy is not always feasible and a single aminoglycoside treatment can cause permanent damage to the inner ear [4]. Therefore, research efforts have focused on elucidating the mechanisms underlying aminoglycoside-induced HC death, to identify therapeutic targets to mitigate ototoxicity. These studies have established that HCs are susceptible to aminoglycoside toxicity, due to the abundance of HC specific mechanoelectro-transduction (MET) channels that facilitate rapid aminoglycoside entry into the cell [5, 6]. Once the aminoglycoside has entered the HC, it targets and damages the mitochondrial ribosome, preventing mitochondrial protein synthesis.

Aminoglycoside-induced mitochondrial damage is linked with the drugs’ antibiotic mechanism. Specifically, aminoglycosides bind to the A-site on the 16S ribosomal RNA of the 30S ribosome, inhibiting bacterial protein synthesis and killing the bacteria [7]. Shared ancestry between mitochondria and bacteria means that the mitochondrial ribosome is similar to the bacterial ribosome, and therefore susceptible to aminoglycoside binding. Aminoglycoside-induced disruption of mitochondrial protein synthesis is subsequently detected by innate cellular monitoring systems, initiating cell signalling cascades that result in HC death.

Cell death pathways are not well-defined in the inner ear. However, it is known that excessive mitochondrial ROS production and subsequent cellular oxidative stress is a key aspect of the process [8–10]. As a result, research aiming to mitigate ototoxicity has predominantly focused on antioxidant compounds, with equivocal and often conflicting outcomes [11]. These studies have not translated to changes in medical care, and in some cases, antioxidant use was associated with serious side effects, such as bleeding, pain, and gastric distress [11]. It is unclear why antioxidant therapies that have been effective in vitro have not achieved particularly good outcomes in vivo. However, normal ROS production is an integral part of cellular and physiological function; thus, antioxidant therapies can induce damaging reductive cell stress [12].

In addition to ROS production, the activation of c-Jun N-terminal kinases (JNK) and p38 mitogen-activated protein kinase (P38) has been reported in aminoglycoside-treated HCs; and various JNK and P38 inhibitors attenuate aminoglycoside-induced HC death [13–17]. However, JNK and P38 have critical homeostatic functions, meaning that inhibition can have toxic effects in other tissues, such as the liver and spiral ganglion neurons [18, 19]. Therefore, upstream molecules that drive the apoptosis-specific roles of JNK and P38 might represent better targets for ameliorating aminoglycoside-induced HC death. Recently, Tao et al. demonstrated that apoptosis signal-regulating kinase 1 (ASK1) was the only mitogen-activated protein kinase kinase (MAP3K) to have significantly increased RNA expression after aminoglycoside treatment in HCs [20]. ASK1 is activated by redox imbalance and activates downstream MAP kinases, particularly JNK and P38. In addition, multiple ASK1 inhibitors have been developed, with encouraging results in human clinical trials [21]. Therefore, ASK1 inhibition may be a novel strategy for preventing aminoglycoside-induced HC death.

Ask1 is expressed throughout the murine cochlear epithelium, including IHCs and OHCs [22–24] (data may be viewed at https://umger.org/index.html?layout_id= f64f9c22&gene_symbol=map3k5&gene_symbol_exact_match=0). However, the role of ASK1 as a mediator of aminoglycoside-induced HC death has not been investigated. Furthermore, the role of ASK1 in normal auditory function has not been defined. Therefore, this study aimed to evaluate the importance of ASK1 in the mouse HC by characterising the auditory phenotype of Ask1−/− mice and examining whether Ask1−/− HCs are resistant to aminoglycoside toxicity. The utility of pharmacologically-mediated ASK1 inhibition was also tested for preventing aminoglycoside-induced HC death.

Methods

Detailed methodology is provided in Supplementary Material 1.
Table 1  The reported prevalence of ototoxic outcomes in humans treated with aminoglycosides. The American Speech Language Hearing Association (ASHA) definition of ototoxicity is described as a hearing threshold shift $\geq 20$ dB in one frequency; $\geq 10$ dB at any two adjacent frequencies, or loss of response at three consecutive frequencies [25]. However, numerous studies use different definitions of ototoxicity

| Aminoglycoside | Prevalence of ototoxic outcomes | Number in sample | Described method for identifying ototoxicity | Definition of ototoxicity                                                                                                                                                                                                 | Average duration of therapy | Dosage              | Ref |
|----------------|--------------------------------|------------------|---------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------|---------------------|-----|
| Amikacin       | 75%                            | 38/51            | Audiometry 250–8000 Hz                      | Hearing was classified as normal (0–20 dB) or impaired (≥ 21 dB) using the Namibian Ministry of Health & Social Services audiogram chart                                                                                                                                   | 6–8 months                  | 15 mg/kg/day        | [26] |
| Amikacin       | 70%                            | 29/41            | Audiometry 250–8000 Hz                      | ASHA 1994 Definition                                                                                                                                                                                                     | 45 days (range 13–131)      | 500 mg/day          | [27] |
| Amikacin       | 62%                            | 270/437          | High frequency audiometry or diagnosed by the treating physician | Hearing threshold shift $\geq 15$ dB at two or more frequencies or an increase $\geq$ than 20 dB at one frequency; or the absence of usable hearing acquired during or soon after amikacin treatment                                                                 | 167 days (range 105–210)    | 15 or 25 mg/kg/day | [28] |
| Amikacin       | 55%                            | 12/22            | Audiometry 250–8000 Hz                      | Neurosensory hearing loss $\geq 20$ dB at any frequency                                                                                                                                                                    | 20 weeks (range 1–43)       | 75 mg/kg/week       | [29] |
| Amikacin       | 51%                            | 20/39            | Audiometry 250–8000 Hz                      | Hearing threshold shift $\geq 15$ dB at one frequency in one ear or $\geq 10$ dB at three frequencies in one ear                                                                                                        | 20 days (range 4–83)        | 7.5 mg/kg/12 h     | [30] |
| Amikacin       | 33%                            | 13/39            | Audiometry 250 Hz–20 kHz                    | ASHA 1994 definition                                                                                                                                                                                                     | $>4$ days                   | not defined         | [31] |
| Amikacin       | 30%                            | 7/23             | Audiometry 250–8000 Hz, caloric-evoked nystagmus & cVEMP | Not defined                                                                                                                                                                                                                | 40 days (range 15–84)       | 7.5 mg/kg/8 h      | [32] |
| Amikacin       | 35%                            | 6/17             | Audiometry 250 Hz–20 kHz                    | Hearing threshold shift $\geq 15$ dB at two frequencies                                                                                                                                                                   | $8$ days $\pm$ 3.3          | 7.5 mg/kg/12 h     | [33] |
| Amikacin       | 25%                            | 6/24             | Audiogram                                   | ASHA 1994 definition                                                                                                                                                                                                     | 28 days                     | 15 mg/kg/day       | [34] |
| Amikacin       | 21%                            | 6/28             | Caloric stimulation                         | No response to caloric test                                                                                                                                                                                                | 3 days                      | 15 mg/kg/day       | [35] |
| Amikacin       | 18%                            | 7/40             | Audiometry 250–8000 Hz                      | Hearing thresholds outside the normal 0–15 dB range for children at 6–8 kHz                                                                                                                                              | $5$ days $\pm$ 2            | 15 mg/kg/day       | [36] |
| Amikacin       | 9%                             | 4/44             | Audiometry 250–8000 Hz                      | Hearing threshold shift $\geq 20$ dB at any frequency                                                                                                                                                                   | 138 days (IQR 70–187)       | 400 mg/day         | [37] |
| Amikacin       | 7%                             | 4/60             | Audiometry 250–8000 Hz                      | Hearing threshold shift $\geq 15$ dB at two or more frequencies                                                                                                                                                           | 10 days                     | 15 mg/kg/day       | [38] |
| Gentamicin     | 53%                            | 8/15             | Prodromal questioning for vestibular signs & high frequency audiometry | Hearing threshold shift $\geq 15$ dB at two frequencies in the same ear or $\geq 10$ dB in two frequencies in both ears. Patients also asked about other ototoxic signs including tinnitus, dizziness, or bobbing oscillopsia                                                                 | $8$ days $\pm$ 4            | 4 mg/kg/day        | [39] |
| Aminoglycoside | Prevalence of ototoxic outcomes | Number in sample | Described method for identifying ototoxicity | Definition of ototoxicity | Average duration of therapy | Dosage | Ref |
|----------------|--------------------------------|-----------------|-----------------------------------------------|--------------------------|---------------------------|--------|-----|
| Gentamycin     | 34%                            | 116/339         | Audiometry 250 Hz–20 kHz                      | ASHA 1994 definition     | > 4 days                  | Not defined | [31]|
| Gentamicin     | 13%                            | 14/106          | Audiometry 250–8000 Hz                        | Hearing threshold shift ≥ 15 dB at both 6 & 8 kHz | 5–7 days                | 80–160 mg/12 h | [40]|
| Kanamycin      | 56%                            | 168/302         | Audiometry 250–8000 Hz                        | Hearing was classified using the Namibian Ministry of Health & Social Services audiogram chart. Normal = 0–20 dB. Impaired ≥ 21 dB | 6–8 months          | 15 mg/kg/day | [26]|
| Kanamycin      | 42%                            | 14/33           | Audiometry 250–8000 Hz                        | Neurosensory hearing loss ≥ 20 dB at any frequency | 14 weeks (range 1–139) | 75 mg/kg/week | [29]|
| Kanamycin      | 22%                            | 5/23            | Audiometry 250–8000 Hz                        | Hearing threshold shift ≥ 20 dB at any frequency | 104 days (range 82–180) | 400 mg/day | [37]|
| Kanamycin      | 20%                            | 9/42            | Audiometry 250–8000 Hz                        | Hearing threshold shift ≥ 20 dB in one frequency or ≥ 15 dB at any two adjacent frequencies | 10 weeks ± 5         | Not defined | [41]|
| Netilmicin     | 47%                            | 7/15            | Prodomal questioning for vestibular signs & high frequency audiometry | Hearing threshold shift ≥ 15 dB at two frequencies in the same ear or ≥ 10 dB in two frequencies in both ears. Patients also asked about other ototoxic signs including tinnitus, dizziness, or bobbing oscillopsia | 11 days ± 4          | 5.5 mg/kg/d | [39]|
| Netilmicin     | 4%                             | 3/68            | Audiometry 250–8000 Hz                        | Hearing threshold shift ≥ 15 dB at two frequencies | 8 days ± 3             | 1.7 mg/kg/ 8 h | [33]|
| Streptomycin   | 60%                            | 3/5             | Audiometry 250–8000 Hz                        | Hearing threshold shift ≥ 20 dB in one frequency; ≥ 15 dB at two frequencies | 10 weeks ± 6         | Not defined | [41]|
| Streptomycin   | 19%                            | 6/32            | Audiometry 250–8000 Hz                        | Hearing threshold shift ≥ 20 dB in one frequency | 11.5 weeks (range 2–107) | 75 mg/kg/week | [29]|
| Tobramycin     | 30%                            | 7/23            | Electronystagmography with caloric irrigation | Reduced labyrinth excitability | Not defined                | Not defined      | [42]|
| Tobramycin     | 19%                            | 19/102          | Audiometry 250–8000 Hz                        | Hearing threshold shift ≥ 15 dB at two frequencies | 8 days ± 3             | 1.7 mg/kg/8 h | [33]|
| Tobramycin     | 18%                            | 5/28            | Audiometry 250–20 kHz                        | ASHA 1994 definition     | > 4 days                  | Not defined | [31]|

Ref: reference, IQR: interquartile range, cVEMP: cervical vestibular-evoked myogenic potential
Study approval

The Murdoch Children’s Research Institute and Sunnybrook Research Institute Animal Ethics Committees approved procedures in project numbers A875, A904, and 21515. The Royal Children’s Hospital (RCH) Human Research Ethics Committee approved sputum collection in project number 25054.

Mice

*Ask1*−/− mice were generated previously [43] and back-crossed for >12 generations onto the C57BL/6 background. Wild type (WT) C57BL/6 mice were purchased from the Walter and Eliza Hall Institute of Medical Research (Parkville, Australia) and used as experimental controls. CD-1 mice were purchased from Charles River Laboratories (Raleigh, USA).

Acoustic startle response (ASR) and auditory brainstem response (ABR)

ASRs were measured using the SR-LAB system (San Diego Instruments) as described in [44]. ABRs were measured using an evoked potentials workstation and BioSigRP Stimulate/Record System v4.4.1 (Tucker Davis Technologies). Sound pulses were presented to anaesthetised mice, in short bursts (100 µs duration, repeated 512 times), through a free-field magnetic speaker (model FF1, Tucker Davis Technologies) 10 cm from the mouse’s left ear. Hearing thresholds were defined as the lowest sound pressure level capable of eliciting a visible ABR.

Tissue collection and analysis

Adult mice were euthanised by anaesthetic overdose and perfused with 10% NBF. Dissected cochleae were decalcified in 10% EDTA (7 days at 4 °C), oriented in 1% agarose in cryomolds (Sakura Finetek, Torrance, CA, USA) and paraffin-embedded. A microtome cut 2-µm sections parallel to the modiolus. Sections were stained with hematoxylin and eosin (H&E).

Neonatal mouse neurosensory epithelium dissection, culture, and processing

See Ogier et al. 2019 protocol [45] for stepwise method. Pups were euthanised by decapitation and cochlear explants were collected for organotypic culture. For *Ask1*−/−-WT comparisons, explants were cultured overnight before fresh media was added containing neomycin or vehicle (DMSO/saline). For ASK1 inhibition experiments, explants were cultured 3–4 h, before being treated for 16 h with GS-444217 (supplied by Gilead Sciences, San Francisco, CA). Fresh media was added containing GS-444217 and the associated treatment. Explants were fixed and stained (as per Supplementary Material Table 1). For HC quantification, images from the explant base to apex were photo-stitched together and de-identified. Fiji software was used to draw two boxes (0.18 mm x 0.09 mm), which were aligned and overlaid either side of the explant mid-point. HCs were counted using the Fiji cell count tool, including cells with > half the cell body inside the rectangle boundary. The average HC number of the two boxes was recorded for each explant.

Western blot analysis

Protein was extracted from three pooled explants per treatment, producing ~1 ng/ml protein per sample. Ten micrograms protein was denatured and separated in a precast Gel (Bio-Rad Cat#4,561,093). Protein was transferred onto a 0.45 µm pore PVDF membrane (Immobilon-P, Cat#IPVH00010). Antibodies were incubated as per Supplementary Material Table 1. Relative quantification of steady state protein levels was performed by first normalising to the loading control, and then to a non-treated negative control within each blot.

Antibiotic minimum inhibitory concentration assay

Antibiotic efficacy was tested against a blood isolate *Pseudomonas aeruginosa* reference strain (American type culture collection, 27853-provided by the RCH Department of Microbiology) and two clinical isolates (0307 and 0315 provided by RCH Respiratory and Sleep Medicine, having been collected by the Australian Respiratory Early Surveillance Team for Cystic Fibrosis and isolated by RCH pathology). A 96-well plate containing serial 1:2 dilutions of amikacin, tobramycin or neomycin and GS-444217 was inoculated with *P. aeruginosa* and incubated at 37 °C for 16 h. The minimum inhibitory concentration (MIC) was defined as the amount of antibiotic required to prevent bacterial metabolism of resazurin, as measured by fluorescence (540 nm excitation and 580 nm emission) on an Infinite M200 Pro plate reader (Tecan life Sciences).

Statistics

ABR and ASR data was compared between groups for each frequency/volume tested using unpaired *T* tests (with the Holm Sidak correction for multiple comparisons). Protein
levels were compared using a standard two-way ANOVA with Sidak’s multiple comparison test. A standard two-way ANOVA was used to identify changes in MICs and post hoc T tests were performed using the two-stage step-up false discovery method of Benjamini, Krieger, and Yekutieli. These analyses were performed using GraphPad prism (version 7.0a for Mac). HC counts were analysed with a three-way analysis of variance, before pairwise Fisher individual tests of the differences of means were performed to ascertain p values for strain/treatment. This analysis was performed in Minitab software (version 17 for Windows) under the guidance of Dr. Sue Finch, Melbourne University Statistical Consulting Platform.

Results

Ask1−/− cochlear morphology and HCs appear normal

No gross deformities were noted during dissection, nor in sectioned Ask1−/− cochleae, compared to WT controls (Fig. 1A). Myosin VIIa-staining of cochlear explants dissected from neonatal (P4) mice showed HCs in typical formation, in both WT and Ask1−/− explants (Fig. 1B). Phalloidin staining of P3 explants showed stereocilia on the apical HC surfaces of both WT and Ask1−/− explants (Fig. 1C).

Functional assessment of hearing in Ask1−/− mice

The acoustic startle response (ASR) of male Ask1−/− mice was significantly higher than that of WT controls, suggesting that male Ask1−/− mice are acoustically hypersensitive (Fig. 2A). A similar trend was present in the data from female Ask1−/− mice, although this did not reach statistical significance. As factors unrelated to hearing, such as muscle strength, emotional status, or memory function can contribute to the ASR [46, 47], the auditory brainstem response (ABR) was performed to assess hearing in the Ask1−/− strain. ABR testing showed that there was no difference between Ask1−/− and WT hearing thresholds when measured between 4 and 32 kHz at 4, 10, and 24 weeks of age (Fig. 2B).
Ask1−/− HC are resistant to neomycin-induced cell death

Cochlear explants were cultured overnight before the addition of 1 mM neomycin or vehicle (DMSO). Notable OHC death (as indicated by positive TUNEL staining) occurred 20 h after treatment commenced (Fig. 3A). After 45 h, there was a notable loss of Myosin VIIa-positive HCs and TUNEL staining was prevalent. By 69 h, neomycin caused near-complete loss of Myosin VIIa positive HCs. In comparison, Ask1−/− explants showed a markedly different response to neomycin treatment. There was no observable HC TUNEL stain at the 20 h time point, very little at the 45 h time point and none at the 69 h time point (Fig. 3A). Furthermore, the nuclear compartment of remaining HCs appeared less fragmented at the 20- and 45 h time points in the Ask1−/− group when compared to time-matched controls. However, at the 69 h time point, the nuclei of Myosin VIIa-positive HCs were significantly condensed or fragmented in the Ask1−/− explants (Fig. 3A). These qualitative observations suggested that HC death is delayed in neomycin-treated Ask1−/− explants. This observation also indicated that TUNEL staining was not the most suitable means to assess hair cell death, because hair cells that were lost were not always TUNEL-positive at the time points captured. In contrast, Myosin VIIa immunohistochemistry provided robust and specific hair cell labelling. As a result, the subsequent methodology for quantifying hair cell survival was based on Myosin-VIIa staining.

To quantify HC survival, we determined the number of Myosin VIIa positive cells in two 180 μm × 90 μm fields of view in the cochlear mid-turn. Over a time-course of 3 days, there was no significant difference between the HC counts in WT and Ask1−/− explants that had been treated with vehicle only (p = 0.4 (IHC), 0.7 (OHC), two-way ANOVA) (Fig. 3B). In comparison, significant genotype dependent differences were observed after neomycin treatment. At the 24 h time point, 77% ± 3% of IHCs remained in neomycin-treated WT explants, which was significantly less than the neomycin-treated Ask1−/− explants (91% ± 2%) (mean ± SEM, p = 0.006) (Fig. 3B, C). In contrast, there was no significant difference between WT and Ask1−/− IHC counts at the 48- and 72 h time points (p = 0.8 and 0.7 respectively) (Fig. 3B, C). Neomycin-induced OHC death was more pronounced than IHC death in both WT and Ask1−/− explants. However, Ask1−/− OHCs showed resistance to neomycin toxicity, as evidenced by a significantly slower rate of loss when compared to neomycin-treated WT OHCs (Fig. 3B). After 24 h of neomycin treatment, only 52% ± 7% of WT OHCs remained compared with 77% ± 6% of Ask1−/− OHCs (p = 0.02). The difference was not significant at the 48 h time point, with 19% ± 4% of WT OHCs persisting compared to 26% ± 3% Ask1−/− OHCs (p = 0.2). After 3 days of neomycin treatment, only 3% ± 1% of the OHCs remained in WT explants compared to 16% ± 2% in the Ask1−/− explants (p = 0.0002) (Fig. 3C).
ASK1 inhibition protects WT HCs from neomycin toxicity

Having demonstrated that a genetic-mediated reduction in ASK1 affords protection against neomycin-induced HC death in vitro, we hypothesised that a small-molecule inhibitor of ASK1 (GS-444217) would also protect WT (C57BL/6) HCs against neomycin toxicity in vitro.

To test if treatment with GS-444217 could compromise HC survival, cochlear explants were cultured for 24 h with GS-444217 doses ranging from 0 to 100 μM. There was no evidence of increased HC death as a result of GS-444217 treatment (one-way ANOVA; OHC counts \( p = 0.36 \), IHC counts \( p = 0.27 \)) (Fig. 4A, B, blue line).

Next, we investigated if treatment with GS-444217 could protect against aminoglycoside-induced HC death in vitro. Cochlear explants were pre-treated for 16 h with GS-444217 (0 μM-100 μM) or vehicle (DMSO), and then incubated for a further 24 h with the addition of 1 mM neomycin (Fig. 4A, B, orange line). As observed previously (Fig. 3), IHCs were highly resistant to neomycin treatment, with less than 1% of IHCs lost after 24 h neomycin treatment (Fig. 4B). Overall, there was no significant difference (\( p = 0.69 \)) in the number of IHCs in neomycin-treated explants that had been pre-treated with either vehicle (DMSO) or 1 μM GS-444217 pre-treatment markedly improved OHC survival in neomycin-treated explants, with concentrations over 1 μM GS-444217 significantly attenuating OHC death (Fig. 4B, orange line). For explants pre-treated with vehicle (DMSO) before being exposed to 1 mM neomycin, only 38.1 ± 4.8 Myosin VIIa-positive OHCs remained at the 24 h time point. When this number is normalised to untreated controls, a survival rate of 51% is indicated. OHC number increased to 51 ± 2.5 (68% survival) with a pre-treatment of 0.1 μM GS-444217, and 1 μM GS-444217 treatment resulted in 63 ± 2.5 OHCs surviving (92% survival). At a concentration of 100 μM GS-444217 pre-treatment, 68 ± 1.4 OHCs survived, representing 95% cell survival when compared to the DMSO treated controls (Fig. 4B).
Over a 3-day neomycin treatment period, 100 μM GS-444217 afforded significant protection for both IHCs and OHCs (Fig. 4C, D). There was no difference in IHC survival at the 24- and 48 h time points. However, after 72 h of neomycin treatment, an average of 10.2 ± 1.7 IHCs were counted in the field of view for vehicle pre-treated explants, compared to 15.3 ± 0.6 in the GS-444217 pre-treated explants (p < 0.001). The effect of GS-444217 pre-treatment was more pronounced in the OHCs, protecting against neomycin treatment at every time point tested (Fig. 4D). After 24 h, the average OHC counts for vehicle pre-treated explants was 38.1 ± 4.8 compared to 68.2 ± 1.3 in the GS-444217 pre-treated explants (p < 0.001). At 48 h, only 25 ± 2.2 OHCs persisted in the vehicle pre-treated explants compared to 41.8 ± 5.9 in the GS-444217 pre-treated group (p = 0.04) and after 72 h neomycin treatment, 16.2 ± 1.9 OHCs remained in the vehicle group, compared to 32.1 ± 4.2 in the GS-444217 group (p = 0.01).

**Protective effect of GS-444217 in cochlear explants**

To investigate how GS-444217 reduces neomycin-induced hair cell death, we performed immunohistochemistry and western blot analysis. As previously observed in our ASK1 genetic knockout experiments (Fig. 3), ASK1 inhibition using GS-444217 limited canonical apoptosis (indicated by TUNEL staining) (Fig. 5A). Immunohistochemistry also showed that GS-444217 pre-treatment limited neomycin-induced ASK1 phosphorylation in cochlear hair cells (Fig. 5B). Western blot analysis of WT cochlear explants that were pre-treated with GS-444217 and then cultured for 24 h with either vehicle (DMSO) or 1 mM neomycin indicated a significant reduction of p-P38 when explants were pre-treated with GS-444217 in DMSO co-treated culture conditions (Fig. 5C). A similar trend of reduced p-P38 in GS-444217 pre-treated explants was observed in explants cultured with neomycin. Likewise,
To evaluate the possibility that GS-444217 could have an off-target effect upon antibiotic action, the minimum inhibitory concentration (MIC) of amikacin, tobramycin, and neomycin against Pseudomonas aeruginosa (P. aeruginosa) was determined. P. aeruginosa is the most common cause of chronic lung infections in individuals with cystic fibrosis and these individuals are particularly susceptible to aminoglycoside-induced hearing loss, due to long-term aminoglycoside treatment [50]. One reference strain (ATCC 27853) and two clinical isolates (0307 and 0315) were utilised. Tobramycin and amikacin were tested because they are the most clinically utilised aminoglycosides for P. aeruginosa treatment. Neomycin was also tested as an aminoglycoside frequently used in the laboratory. The broth dilution test demonstrated that GS-444217 co-treatment did not significantly change the minimum antibiotic concentration required for any antibiotic tested to inhibit resazurin metabolism in all three P. aeruginosa strains (Fig. 6).

**Discussion**

This study utilised Ask1−/− mice and a small-molecule inhibitor of ASK1 (GS-444217) to test if the downregulation of ASK1 attenuates aminoglycoside-induced HC death. Both genetic and pharmacological approaches demonstrated that ASK1 has an important role in the process of HC death and indicated that ASK1 inhibition could limit aminoglycoside ototoxicity.

Prior to this work, the effect of Ask1 knockout on auditory function had not been investigated. We used a combination of histology, immunohistochemistry, and functional ABR testing to demonstrate that Ask1 knockout does not compromise the peripheral auditory structures or hearing thresholds of mice. However, male Ask1−/− mice presented with a hypersensitive startle response when compared to WT controls, and a similar trend was observed in the female cohort. It is difficult to predict what the underlying cause of the unusually strong ASR might be, because auditory signal integration and efferent control is not well understood [51]. High ASR’s generally indicate neural processing dysfunction in an auditory or psychiatric disorder [52], whilst factors such as muscle strength, emotional status, and memory function can also affect the ASR [46, 47]. Notably, abnormal behaviour in Ask1−/− mice has been previously reported, including hyperactivity, enhanced motor coordination, and significantly increased dopaminergic transmission [53]. ASK1 deficiency has also been implicated with impaired sensory gating in individuals with schizophrenia [54] and an ASK1 polymorphism is associated with reduced cognitive empathy in men [55]. Combined, these observations suggest that ASK1 may play a role in neuronal signalling. Whilst this has not yet been directly investigated, Ask1−/− mice could prove useful for further exploration of neuronal development and signal processing mechanisms.

The major aim of this study was to investigate the potential role of ASK1 in aminoglycoside-induced HC death. Analysis
A  

**TOBRAMICIN MICs**

- Isolate 0307
- Isolate 0315
- ATCC 27853

| MIC (µg/ml) | 0 | 0.1 | 10 | 100 |
|------------|---|-----|----|-----|
| Isolate 0307 | 8 | 8 | 8 | 8 |
| Isolate 0315 | 4 | 4 | 4 | 4 |
| ATCC 27853   | 2 | 2 | 2 | 2 |

B  

**AMIKACIN MICs**

- Isolate 0307
- Isolate 0315
- ATCC 27853

| MIC (µg/ml) | 0 | 0.1 | 10 | 100 |
|------------|---|-----|----|-----|
| Isolate 0307 | 64 | 64 | 64 | 64 |
| Isolate 0315 | 32 | 32 | 32 | 32 |
| ATCC 27853   | 16 | 16 | 16 | 16 |

C  

**NEOMICIN MICs**

- Isolate 0307
- Isolate 0315
- ATCC 27853

| MIC (µg/ml) | 0 | 0.1 | 10 | 100 |
|------------|---|-----|----|-----|
| Isolate 0307 | 256 | 256 | 256 | 256 |
| Isolate 0315 | 128 | 128 | 128 | 128 |
| ATCC 27853   | 64  | 64  | 64  | 64  |
of Ask1−/− cochlear explants demonstrated that Ask1 deficiency significantly attenuates neomycin-induced OHC death. Ask1 deficiency also afforded some protection against neomycin-induced IHC death; however, this was less pronounced. Subsequent experiments using GS-444217 produced results that correlated with the genetic ablation data. However, HC survival appeared slightly higher in the pharmacological data. The main methodological difference between these independent experiments was the addition of DMSO, used as a vehicle for GS444217. DMSO is a potent antioxidant that has previously been shown to increase hair cell survival [56–58]. Therefore, the DMSO used in the GS444217 pre-treatment/control may account for any improvement of HC survival during pharmacological experiments. Overall, GS-444217 pre-treatment resulted in significantly more OHCs surviving 3 days of neomycin treatment, when compared with DMSO pre-treated controls. However, neither genetic knockout nor pharmacological inhibition of ASK1 completely attenuated HC death. This suggests that alternate mechanisms, such as MAPK independent caspase activation, may be removing HCs. Alternatively, damaged HCs can be phagocytosed by cochlear-resident macrophages or supporting cells [59, 60]. Western blot analysis indicated that P38 and JNK phosphorylation occurred in GS-444217-treated explants, which correlates with previous studies that utilised Ask1−/− mice and ASK1 inhibitors in alternate disease models [43, 61, 62]. Therefore, it is likely that ASK1 independent mechanisms are able to activate the P38 and JNK pathways in cochlear explants. Nevertheless, the increased HC survival observed in GS-444217-neomycin-treated explants was significant, especially given the non-physiological conditions in which cochlear explants are cultured. In particular, the experimental dose of 1 mM neomycin—applied directly to the HCs in vitro—is unlikely to represent the concentration of aminoglycoside found in vivo in cochlear endolymph. This experimental dose is used in vitro to achieve clear results in a limited experimental timeframe, because optimal HC survival is less than one week in vitro [45]. However, a dose achieving cochlear levels of 1 mM neomycin would not be considered safe for use in humans. Likewise, other clinically utilised aminoglycosides do not reach such high concentrations in vivo. For example, a study of 113 individuals receiving amikacin over a 2-week period demonstrated that average peak plasma concentrations did not exceed 17 μM amikacin [63]. Moreover, the stria vascularis acts as an important blood-barrier in vivo, limiting the amount of aminoglycoside entering the endolymph. Kinetic studies in rats have shown that a gentamicin plasma level of 13–14 μM achieves only 3.1 μM in the perilymph and 2.5 μM in the endolymph [64]. Similar results have been observed in the guinea pig, with intravenous gentamicin (300 mg/kg) achieving a peak plasma concentration of 1.1 mM, but only 0.3 mM in the cochlear lymph 3 h after treatment [65]. Therefore, the otoprotective effect of GS-444217 may be stronger in vivo, where HCs are likely to be exposed to significantly lower aminoglycoside concentrations than those used in this in vitro study.

To further investigate the utility of pharmacological inhibition of ASK1 as a protective strategy against aminoglycoside ototoxicity, we tested whether GS-444217 altered the efficacy of aminoglycosides against P. aeruginosa in vitro. Notably, these data indicated that 100 μM GS-444217 did not impair antibiotic efficacy, whereas 1 μM GS-444217 significantly attenuated neomycin-induced HC death. In combination, these results suggest that GS-444217 could be used to prevent aminoglycoside-induced HC death without impacting primary aminoglycoside care. Whilst this must be assessed in vivo, the promising safety of ASK1 inhibitors taken orally in clinical trials, combined with the observation that GS-444217 does not affect aminoglycoside antibiotic efficacy in vitro, implies that ASK1 inhibition could be applied as an otoprotective strategy in the clinic. Further studies are now needed to confirm that GS-444217 and other promising ASK1 inhibitors do not impair antibiotic efficacy against common infections, such as Group B streptococcus, E. coli, Staphylococcus aureus, or Enterobacteriaceae infection. These organisms often cause sepsis in neonates and subsequent aminoglycoside treatment is the greatest risk factor for these newborns developing hearing loss [66–68].

Collectively, our data provide compelling evidence that ASK1 inhibition may be a valid strategy for mitigating aminoglycoside-induced hearing loss in humans. Whilst previous studies have demonstrated the safety of ASK1 inhibition in human clinical trials [21], strong in vivo efficacy data is required to provide the evidence base for clinical testing of ASK1 inhibition in aminoglycoside-treated individuals. In particular, the inhibitor dosing schedule required to achieve meaningful auditory protection must be determined. Based on the safety results of human clinical trials to date, we anticipate the minimum dose of an ASK1 inhibitor will have no effect on the innate immune response; however, this needs to be fully evaluated in vivo. In this study, we have demonstrated that 1 μM of GS-444217 significantly attenuates HC death caused by 1 mM neomycin treatment. However, a trend of improved HC survival was also achieved using only 0.1 μM GS-444217. It is difficult to predict the exact GS-444217 dosing regimen that will be required to achieve similar cochlear concentrations in vivo; however, previous studies have achieved GS-444217 plasma concentrations markedly lower than these concentrations, indicating that significantly lower aminoglycoside concentrations than those used in this in vitro study.
higher than 1 μM. For example, a single oral dose of 50 mg/kg GS-444217 resulted in plasma levels of 92.8 mM in mice [69]. In rats, a single oral dose of 30 mg/kg, achieved peak plasma concentrations approaching 100 μM, although GS-444217 plasma levels declined to approximately 0.1 μM after 24 h [70]. This indicates that twice daily GS-444217 dosing may be beneficial. Other ASK1 inhibitors have also been tested in vivo, with 30 mg/kg of GS-459679 achieving plasma concentrations of approximately 6 μM in mice, 6.5 h after administration [71]. Unfortunately, a conspicuous limitation for in vivo testing of ASK1 inhibition as an otoprotective strategy is that mice appear to be intrinsically resistant to aminoglycoside-induced HC death [72]. Therefore, additional models are required to generate the necessary pre-clinical data. The pig may be appropriate, as the porcine metabolic rate, immune system, cochlea, and auditory range closely mimic that of humans [73, 74]. In addition, swine models of cystic fibrosis exist that may be valuable for studying the progression of infection and the efficacy of aminoglycoside antibiotics when an adjuvant ASK1 inhibitor is used [75]. A porcine model could also provide information regarding the benefits of ASK1 inhibition in regard to other aminoglycoside toxicities, such as aminoglycoside nephron and neurotoxicity.

This work provides a strong foundation to justify the development of a hypothetical model that may lead to the development of an adjuvant otoprotective therapy. Such a therapy would have far-reaching implications, as aminoglycoside ototoxicity is a significant health issue, not only for those directly affected, but also clinical health care providers and the economy in general. Avoiding the distressing and lifelong co-morbidities of acquired hearing loss, such as loneliness, impaired mobility, mental fatigue, cognitive decline, and increased mortality risk, is critically important for the health of an individual. From an economic perspective, mitigating aminoglycoside ototoxicity will reduce the financial burden of acquired hearing loss within the national health, education, and welfare systems. In the case of critical healthcare, the prevention of aminoglycoside ototoxicity may also improve the utility of aminoglycoside antibiotics. At present, clinicians must consider the risk of permanent hearing loss against the risk to life when prescribing an aminoglycoside treatment. However, reducing ototoxic outcomes would ease the burden experienced by clinicians during this decision-making process and potentially allow for the wider application of aminoglycoside therapy.

Supplementary information The online version contains supplementary material available at https://doi.org/10.1007/s00109-022-02188-1.

Acknowledgements The authors thank the AREST CF participants, and RCH pathology, animal house staff, Matthew Burton, Dr Sue Finch, and Rosemary Carzino for providing support and/or services used in this project.

Author contribution Jacqueline Ogier: conceptualisation, data curation, formal analysis, funding acquisition, investigation, project administration, methodology, visualisation, writing (original draft, review, and editing). Yuying Gao: conceptualisation, data curation, investigation, methodology, and draft review. Eileen Dunne: conceptualisation, methodology, resources, and draft review. Michael Wilson: conceptualisation and draft review. Gregory H Tesch: conceptualisation, resources, and draft review. David J Nikolic Paterson: conceptualisation, resources, and draft review. Alain Dabdoub: methodology, funding, and resources. Rachel Burt: conceptualisation, methodology, supervision, funding acquisition, resources, and draft review. Bryony Nayagam: conceptualisation, methodology, supervision, funding acquisition, resources, and draft review.

Funding Open Access funding enabled and organized by CAUL and its Member Institutions. The authors are supported by the Garnett Passe and Rodney Williams Memorial Foundation (PhD Research scholarship to JMO) Research Fellowship to BAN, the Vincent Chiodo Foundation (PIL), and the Koerner Foundation (AD). Additional infrastructure funding to the Murdoch Children’s Research Institute was provided by the Australian Government National Health and Medical Research Council Independent Research Institute Infrastructure Support Scheme and the Victorian Government’s Operational Infrastructure Support Program.

Data availability Important data generated or analysed during this study is included in this published article. Further information is available from the corresponding author on reasonable request.

Declarations

Ethics approvals, patient consent, and consent to publish The Murdoch Children’s Research Institute Animal Ethics Committee approved mouse procedures in project numbers A875 and A904, in compliance with the Australian Code of Practice for the Care and Use of Animals for Scientific Purposes, 2013. The Sunnybrook Research Institute (SRI) Animal Care Committee approved mouse procedures in protocol number 21515, conforming with Canadian Council on Animal Care requirements. The Royal Children’s Hospital (RCH) Human Research Ethics Committee approved the collection of sputum specimens in project number 25054. Clinical specimens were collected in accordance with the National Health and Medical Research Council’s Statement on Ethical Conduct in Human Research, 2007 (2018 Update) and the Australian Code for the Responsible Conduct of Research, 2018. Written approval for collection, research, and publication using participant sputum samples was given by the parents of participants (signed informed consent forms).

Conflict of interest The authors declare no competing interests.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended
References

1. Grill MF, Maganti RK (2011) Neurotoxic effects associated with antibiotic use: management considerations. Br J Clin Pharmacol 72:381–393. https://doi.org/10.1111/j.1365-2125.2011.03991.x

2. HayMcCutcheon JM, Reed PE, Cheimariou S (2018) Positive social interaction and hearing loss in older adults living in rural and urban communities. J Speech Lang Hear Res 61:2138–2145. https://doi.org/10.1044/2018_JSLHR-H-17-0485

3. Dammeyer J, Crowe K, Marschak M, Rosica M (2019) Work and employment characteristics of deaf and hard-of-hearing adults. J Deaf Stud Deaf Educ 24:386–395. https://doi.org/10.1093/deafed/enz2018

4. Rajendran V, Roy FG (2010) Comparison of health related quality of life of primary school deaf children with and without motor impairment. Ital J Pediatr 36:75. https://doi.org/10.1186/1824-7288-36-75

5. Huth ME, Han K-H, Soutoudeh K et al (2015) Designer aminoglycosides prevent cochlear cell loss and hearing loss. J Clin Invest 125:583–592

6. Wang Q, Stegner PS (2009) Trafficking of systemic fluorescent gentamicin into the cochlea and hair cells. J Assoc Res Otolaryngol 10:205–219. https://doi.org/10.1007/s10162-009-0160-4

7. Cabañas MJ, Vázquez D, Modolell J (1978) Inhibition of ribosomal translocation by aminoglycoside antibiotics. Biochem Biophys Res Commun 83:991–997. https://doi.org/10.1016/0006-291x(78)91493-6

8. Clerici WJ, Hensley K, DiMartino DL, Butterfield DA (1996) Stimulation of free radical formation by aminoglycoside antibiotics. Hear Res 128:112–118. https://doi.org/10.1016/0378-5955(96)00071-8

9. Hammill TL, Campbell KC (2018) Protection for medication-induced hearing loss: the state of the science. Int J Audiol 57:S67–S75. https://doi.org/10.1080/149920007.2018.1455114

10. Villanueva C, Kross RD (2012) Antioxidant-induced stress. Int J Mol Sci 13:2091–2109. https://doi.org/10.3390/ijms13022091

11. Bas E, Van De Water TR, Gupta C et al (2012) Efficacy of three drugs for protecting against gentamicin-induced hair cell and hearing losses. Br J Pharmacol 166:1888–1904. https://doi.org/10.1111/j.1476-5381.2012.01890.x

12. Ylikoski J, Xing-Qun L, Virkkala J, Pirvola U (2002) Blockade of c-Jun N-terminal kinase pathway attenuates gentamicin-induced cochlear and vestibular hair cell death. Exp Brain Res 143:71–81. https://doi.org/10.1007/s00221-001-08380-0

13. Pirvola U, Xing-Qun L, Virkkala J et al (2000) Rescue of hearing, auditory hair cells, and neurons by CEP-1347/KT7515, an inhibitor of c-Jun N-terminal kinase activation. J Neurosci 20:43–50. https://doi.org/10.1523/JNEUROSC.20-01-00043.2000

14. Francis SP, Katz J, Fanning KD et al (2013) A novel role of cytosolic protein synthesis inhibition in aminoglycoside ototoxicity. J Neurosci 33:3079–3093. https://doi.org/10.1523/JNEUROSCI.3430-12.2013

15. Sugahara K, Rubel EW, Cunningham LL (2006) JNK signaling in neomycin-induced vestibular hair cell death. Hear Res 221:128–135. https://doi.org/10.1016/j.heares.2006.08.009

16. Tesch GH, Ma FY, Nikolic-Paterson DJ (2016) ASK1: a new therapeutic target for kidney disease. Am J Physiol Renal Physiol 311:F373–F381. https://doi.org/10.1152/ajprenal.00208.2016

17. Bodmer D, Gloddek B, Ryan AF et al (2002) Inhibition of the c-Jun N-terminal kinase signaling pathway influences neurite outgrowth of spiral ganglion neurons in vitro. Laryngoscope 112:2057–2061. https://doi.org/10.1097/00005537-200211000-00028

18. Tselis A, Megié N (2015) Early transcriptional response to aminoglycoside antibiotic suggests alternate pathways leading to apoptosis in sensory hair cells. Front Cell Neurosci 9:190. https://doi.org/10.3389/fncel.2015.00190

19. Ogier JM, Nayagam BA, Lockhart PJ (2020) ASK1 inhibition: a therapeutic strategy with multi-system benefits. J Mol Med (Berl) 98:335–348. https://doi.org/10.1007/00109-020-01878-y

20. Elkon R, Milon B, Morrison L et al (2015) RFX transcription factors are essential for hearing in mice. Nat Commun 6:8549

21. Cai T, Jen H-I, Kang H et al (2015) Characterization of the transcriptome of nascent hair cells and identification of direct targets of the Atoh1 Transcription Factor. J Neurosci 35:5870

22. Liu H, Chen L, Giffen KP et al (2018) Cell-specific transcriptome analysis shows that adult pillar and Deiters’ cells express genes encoding machinery for specializations of cochlear hair cells. Front Mol Neurosci 11:356. https://doi.org/10.3389/fnmol.2018.00356

23. American Speech-Language-Hearing Association (1994) Audiologic management of individuals receiving cochleotoxic drug therapy [Guidelines]. Available from www.asha.org/policy (https://doi.org/10.1044/policy.GL1994-0003)

24. Sagwa EL, Ruswa N, Mavhunga F et al (2015) Comparing amikacin and kanamycin-induced hearing loss in multidrug-resistant tuberculosis treatment under programmatic conditions in a Namibian retrospective cohort. BMC Pharmacol Toxicol 16:36

25. Javadi MR, Abtahi B, Ghomali K et al (2011) The incidence of amikacin ototoxicity in multidrug-resistant tuberculosis patients. Iran J Pharm Res 10:905–911

26. Modongo C, Sobota RS, Kesenogile B et al (2014) Successful MDR-TB treatment regimens including Amikacin are associated with high rates of hearing loss. BMC Infect Dis 14:542

27. Peloquin CA, Berning SE, Nitta AT et al (2004) Aminoglycoside toxicity: daily versus thrice-weekly dosing for treatment of mycobacterial diseases. Clin Infect Dis 38:1538–1544. https://doi.org/10.1086/420742

28. Perslouph U, Laurell G, Björkholm M (1993) Monitoring of hearing during treatment of leukaemia with special reference to the use of amikacin. J Intern Med 233:401–407. https://doi.org/10.1111/j.1365-2796.1993.tb00691.x

29. Fausti SA, Henry JA, Helt WJ et al (1999) An individualized, sensitive frequency range for early detection of ototoxicity. Ear Hear 20:497–505. https://doi.org/10.1097/00003486-199912000-00005

30. Chen KS, Bach A, Shoup A, Winick NJ (2013) Hearing loss and vestibular dysfunction among children with cancer after receiving aminoglycosides. Pediatr Blood Cancer 60:1772–1777. https://doi.org/10.1002/pbc.24631

31. Gatell JM, Ferran F, Araujo V et al (1987) Univariate and multivariate analyses of risk factors predisposing to auditory toxicity in patients receiving aminoglycosides. Antimicrob Agents Chemother 31:1383–1387. https://doi.org/10.1128/aac.31.9.1383

32. Lee H, Sohn YM, Ko JY et al (2017) Once-daily dosing of amikacin dosing regimens in paediatric surgical patients. Ann Am Thorac Surg 103:1312–1318. https://doi.org/10.1016/j.athoracsur.2016.08.005

33. Forsyth NB, Botha JH, Hadley GP (1997) A comparison of two amikacin dosing regimens in paediatric surgical patients. Ann
Trop Paediatr 17:253–261. https://doi.org/10.1080/02724936.1997.11747896

van Altena R, Dijkstra JA, van der Meer ME et al (2017) Reduced chance of hearing loss associated with therapeutic drug monitoring of aminoglycosides in the treatment of multidrug-resistant tuberculosis. Antimicrob Agents Chemother. https://doi.org/10.1128/AAC.01400-16

Giamarello H, Yiallouros K, Petrikkos G et al (1991) Comparative kinetics and efficacy of amikacin administered once or twice daily in the treatment of systemic gram-negative infections. J Antimicrob Chemother 27 Suppl C:73–79. doi: https://doi.org/10.1093/jac/27.suppl_c.73

Tange RA, Dreschler WA, Prins JM et al (1995) Ototoxicity and nephrotoxicity of gentamicin vs netilmicin in patients with serious infections. A randomized clinical trial. Clin Otolaryngol Allied Sci 20:118–123. https://doi.org/10.1111/j.1365-2273.1995.tb00026.x

Sha S-H, Qiu J-H, Schacht J (2006) Aspirin to prevent gentamicin-induced hearing loss. N Engl J Med 354:1856–1857. https://doi.org/10.1056/NEJMc053428

del Jager P, van Altena R (2002) Hearing loss and nephrotoxicity in long-term aminoglycoside treatment in patients with tuberculosis. Int J Tuberc Lung Dis 6:622–627

Scheenstra RJ, Rijnjtes E, Tavy DLJ et al (2009) Vestibulotoxicity as a consequence of systemically administered tobramycin in cystic fibrosis patients. Acta Otolaryngol 129:4–7. https://doi.org/10.1080/00016480901968534

Ma FY, Tesch GH, Nikolik-Paterson DJ (2014) ASK1/p38 signaling in renal tubular epithelial cells promotes renal fibrosis in the mouse obstructed kidney. Am J Physiol Renal Physiol 307:F1263–F1273. https://doi.org/10.1152/ajprenal.00211.2014

Ogier JM, Carpinelli MR, Arhatari BD et al (2014) CHD7 deficiency in “Looper”, a new mouse model of CHARGE syndrome, results in ossicle malformation, otosclerosis and hearing impairment. PLoS ONE 9:e97559. https://doi.org/10.1371/journal.pone.0097559

Ogier JM, Burt RA, Drury HR et al (2019) Organotypic culture of auditory neurons. Front Cell Neurosci 8:33. https://doi.org/10.3389/fncel.2019.00170

Le Duc J, Fournier P, Hébert S (2016) Modulation of prepulse inhibition and startle reflex by emotions: a comparison between young and older adults. Front Aging Neurosci 13:895. https://doi.org/10.3389/fnagi.2016.00033

Polli E, Angrilli A (2015) Greater general startle reflex is associated with greater anxiety levels: a correlational study on 111 young women. Front Behav Neurosci 9:10. https://doi.org/10.3389/fnbeh.2015.00010

Oliva AA, Atkins CM, Copenhag L, Banker GA (2006) Activated c-Jun N-terminal kinase is required for axon formation. J Neurosci 26:9462

Murai N, Kirkegaard M, Järlebark L et al (2008) Activation of JNK in the inner ear following impulse noise exposure. J Neurotrauma 25:72–77. https://doi.org/10.1089/neu.2007.0346

Ratjen F, Brockhaus F, Angyalosi G (2009) Aminoglycoside therapy against Pseudomonas aeruginosa in cystic fibrosis: a review. J Cyst Fibros 8:361–369. https://doi.org/10.1016/j.jcf.2009.08.004

Lopez-Poveda EA (2018) Olivocochlear efferents in animals and humans: from anatomy to clinical relevance. Front Neurol 9:197. https://doi.org/10.3389/fneur.2018.00197

Swerdlow NR, Braff DL, Geyer MA (2016) Sensorimotor gating of the startle reflex: what we said 25 years ago, what has happened since then, and what comes next. J Psychopharmacol 30:1072–1081. https://doi.org/10.1177/0269881116661075

Kumakura K, Nomura H, Toyoda T et al (2010) Hyperactivity in novel environment with increased dopamine and impaired novelty preference in apoptosis signal-regulating kinase 1 (ASK1)–deficient mice. Neurosci Res 66:313–320. https://doi.org/10.1016/j.neures.2009.12.003

Morris BJ, Pratt JA (2014) Novel treatment strategies for schizophrenia from improved understanding of genetic risk. Clin Genet 86:401–411. https://doi.org/10.1111/cge.12485

Warrier V, Grasby KL, Uzefovsky F et al (2018) Genome-wide meta-analysis of cognitive empathy: heritability, and correlates with sex, neuropsychiatric conditions and cognition. Mol Psychiatry 23:1402–1409

Sanmartín-Suárez C, Soto-Otero R, Sánchez-Sellero I, Méndez-Alvarez E (2011) Antioxidant properties of dimethyl sulfoxide and its viability as a solvent in the evaluation of neuroprotective antioxidants. J Pharmacol Toxicol Methods 63:209–215. https://doi.org/10.1016/j.jptm.2010.10.004

Melki SJ, Heddon CM, Frankel JK et al (2010) Pharmacological protection of hearing loss in the mouse model of endolympathic hydrops. Laryngoscope 120:1637–1645. https://doi.org/10.1002/lary.21018

Momin SR, Melki SJ, Obokhare JO et al (2011) Hearing preservation in Guinea pigs with long-standing endolympathic hydrops. Otol Neurotol 32:1583–1589. https://doi.org/10.1097/MAO.0b013e3182382af64

Hirose K, Rutherford MA, Warchol ME (2017) Two cell populations participate in clearance of damaged hair cells from the sensory epithilia of the inner ear. Hear Res 352:70–81. https://doi.org/10.1016/j.heares.2017.04.006

Kaur T, Hirose K, Rubel EW, Warchol ME (2015) Macrophage recruitment and epithelial repair following hair cell injury in the mouse utricle. Front Cell Neurosci 9:150. https://doi.org/10.3389/fncel.2015.00150

Nakagawa H, Maeda S, Hikiba Y et al (2008) Deletion of apoptosis signal-regulating kinase 1 attenuates acacetaminophen-induced liver injury by inhibiting c-Jun N-terminal kinase activation. Gastroenterology 135:1311–1321. https://doi.org/10.1053/j.gastro.2008.07.006

Yamaguchi O, Higuchi Y, Hirotani S et al (2003) Targeted deletion of apoptosis signal-regulating kinase 1 attenuates left ventricular remodeling. Proc Natl Acad Sci USA 100:15883

Contreras AM, Gamba G, Cortés J et al (1989) Serral trough and peak amikacin levels in plasma as predictors of nephrotoxicity. Antimicrob Agents Chemother 33:973–976. https://doi.org/10.1128/AAC.33.6.973

Tran Ba Huy P, Meulemans A, Wassef M et al (1983) Gentamicin persistence in rat endolymph and perilymph after a two-day constant infusion. Antimicrob Agents Chemother 33:973–976. https://doi.org/10.1128/AAC.23.2.344

Hahn H, Salt AN, Schumacher U, Plonke SK (2013) Gentamicin concentration gradients in scala tympani perilymph following systemic applications. Audiol Neurootol 18:383–391. https://doi.org/10.1159/000355283

Muller-Pebody B, Johnson AP, Heath PT et al (2011) Empirical treatment of neonatal sepsis: are the current guidelines adequate? Arch Dis Child Fetal Neonatal Ed 96:F4

Braye K, Fourreur M, de Waal K et al (2019) Epidemiology of neonatal early-onset sepsis in a geographically diverse Australian health district 2006–2016. PLoS ONE 14:e0214298. https://doi.org/10.1371/journal.pone.0214298

Poonwall N, Navacharoen N, Kangsanarak J, Namwongprom S (2016) Risk factors for hearing loss in infants under universal hearing screening program in Northern Thailand. J Multidiscip Healthc 9:1–5. https://doi.org/10.2147/JMDH.S92818

Budas GR, Boehm M, Kojonazarov B et al (2018) ASK1 inhibition halts disease progression in preclinical models of pulmonary arterial hypertension. Am J Respir Crit Care Med 197:373–385. https://doi.org/10.1164/rccm.201703-0502OC

Liles JT, Corkey BK, Note GT et al (2018) ASK1 contributes to fibrosis and dysfunction in models of kidney disease. J Clin Invest 128:4485–4500. https://doi.org/10.1172/JCI99768

Xie Y, Ramachandran A, Breckenridge DG et al (2015) Inhibitor of apoptosis signal-regulating kinase 1 protects against
acetaminophen-induced liver injury. Toxicol Appl Pharmacol 286:1–9. https://doi.org/10.1016/j.taap.2015.03.019
72. Ogier JM, Lockhart PJ, Burt RA (2020) Intravenously delivered aminoglycoside antibiotics, tobramycin and amikacin, are not oto-toxic in mice. Hear Res 386:107870
73. Heffner HE, Heffner RS (2007) Hearing ranges of laboratory animals. J Am Assoc Lab Anim Sci 46:20–22
74. Bendixen E, Danielsen M, Larsen K, Bendixen C (2010) Advances in porcine genomics and proteomics—a toolbox for developing the pig as a model organism for molecular biomedical research. Brief Funct Genomics 9:208–219. https://doi.org/10.1093/bfgp/elq004
75. Welsh MJ, Rogers CS, Stoltz DA et al (2009) Development of a porcine model of cystic fibrosis. Trans Am Clin Climatol Assoc 120:149–162